Related references
Note: Only part of the references are listed.Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Xiaolei Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
Xing Huang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Yi Yang et al.
CELL RESEARCH (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma
Wu Jingjing et al.
CANCER MEDICINE (2018)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong-Ho Cha et al.
MOLECULAR CELL (2018)
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Jinfang Zhang et al.
TRENDS IN BIOCHEMICAL SCIENCES (2018)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway
Sunbin Ling et al.
MOLECULAR ONCOLOGY (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma
Chang-Long Chen et al.
ONCOIMMUNOLOGY (2016)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1
Zhenghong Lin et al.
CELL DISCOVERY (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Share Paper
